Urinary tract infection

Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection

Retrieved on: 
Friday, April 19, 2024
Research, Infectious Diseases, Hospitals, Clinical Trials, Other Health, Health, Pharmaceutical, General Health, Science, Epidemiology, UTI, Infection, Physician, Harvard University, University, Urinary tract infection, JAMA, Pneumonia, Risk, Hospital, CDC, Bacteria, American Medical Association, Health care, INSPIRE, HCA Healthcare, Workflow, Patient, COVID-19, MPH, UCI, Fungus, Assistant, Harvard Pilgrim Health Care, Harvard Medical School, Journal, Division, Pharmaceutical industry

The two newly published studies, the INSPIRE Pneumonia and UTI Trials, involved more than 220,000 patients with pneumonia or UTI in 59 HCA Healthcare hospitals.

Key Points: 
  • The two newly published studies, the INSPIRE Pneumonia and UTI Trials, involved more than 220,000 patients with pneumonia or UTI in 59 HCA Healthcare hospitals.
  • This resulted in a better match for 28% of pneumonia patients and 17% of patients with UTI when compared to hospitals where physicians were not provided with alerts according to the trials.
  • The INSPIRE trials identified patients with low risk for antibiotic resistance and prompted physicians to order standard-spectrum antibiotics if extended-spectrum antibiotics were being ordered.
  • Additional information about the INSPIRE Pneumonia and UTI Trials can be found in the following JAMA author interview podcast.

ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections

Retrieved on: 
Thursday, April 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Stenotrophomonas maltophilia, Mortality, Genetically modified bacteria, Cefiderocol, Safety, Kidney disease, Infection, Survival, Immunosuppression, Diabetes, Pseudomonas aeruginosa, ECCMID, Head, Urinary tract infection, CHAI, Patient, Hospice and palliative medicine, Gram-negative bacteria, Klebsiella pneumoniae, Chronic obstructive pulmonary disease, Pharmaceutical industry

Please see below under About Cefiderocol for full indications of Fetroja in the U.S.

Key Points: 
  • Please see below under About Cefiderocol for full indications of Fetroja in the U.S.
  • Additionally,19.5% of patients had polymicrobial infections.1
    The study included 261 critically ill adult patients with limited treatment options who received cefiderocol for less than 28 days as part of Shionogi’s Early Access Program in Spain.
  • Real-world evidence is particularly important when reviewing antibiotic use for multidrug-resistant pathogens because of the challenges of conducting randomized clinical trials.
  • We also know how important it is to ensure equitable, global, access to essential medicines like cefiderocol.

HealthTech Leader Cera Strengthens Advisory Board With Addition of New Members

Retrieved on: 
Wednesday, April 17, 2024
Mental Health, Technology, Managed Care, Medical Devices, General Health, Public Policy, Government, Healthcare Reform, Hospitals, Neurology, Health, Health Technology, Telecommunications, Telemedicine, Virtual Medicine, Software, Other Health, Practice Management, Artificial Intelligence, Ed Miliband, NHS, Guardian, COVID, Tech, Peter Mandelson, Policy, House, Magdalen College, Oxford, Advisory board, Innovation, Research, Dementia, Social work, Entrepreneurship, The, A&E, Nursing, Communes of Burundi, Patient, Politics, Pressure, Cabinet, Multimedia, Wood, Urinary tract infection, Cabinet Office, Senior advisor, The Guardian

Cera, the award-winning digital home healthcare provider, today announces the appointment to its Advisory Board of four new members: Lord Wood of Anfield, Hilary Evans, Benjamin Wegg-Prosser and Samantha Jones.

Key Points: 
  • Cera, the award-winning digital home healthcare provider, today announces the appointment to its Advisory Board of four new members: Lord Wood of Anfield, Hilary Evans, Benjamin Wegg-Prosser and Samantha Jones.
  • He was appointed to the House of Lords in 2011 and is a Fellow of Magdalen College, Oxford, and Oxford’s Blavatnik School of Government.
  • Lord Wood will advise Cera as it continues to work collaboratively with government and the NHS to build a healthcare system fit for the future.
  • Since leaving public office full-time, Ms Jones has been appointed as the lead NED at the Department of Health & Social Care.

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Retrieved on: 
Monday, April 22, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Urinary tract infection, Pyelonephritis, WHO, News, World Health Organization, Safety, Infection, European Commission, Bacteria, Inc., AMR, Aztreonam, HAP, Fungal infection, VAP, Hospital-acquired pneumonia, Gram-negative bacteria, Patient, PFE, Ventilator-associated pneumonia, Parasitism, Multiple drug resistance, Virus, Civil service commission, Fungus, Antimicrobial resistance, Head, Disease, Gram, Vaccine

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
  • It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
  • “For healthcare teams treating patients with serious Gram-negative bacterial infections, the prospect of running out of effective treatment options is a daunting but very real threat,” said Yehuda Carmeli, Head, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, Israel, and an investigator in the REVISIT study.
  • Marketing authorization applications for EMBLAVEO are planned for submission in other countries.

Blackmagic Design Announces New Blackmagic URSA Cine 12K

Retrieved on: 
Friday, April 12, 2024
Entertainment, Social Media, Film & Motion Pictures, Hardware, Events, Concerts, Consumer Electronics, Technology, Publishing, TV and Radio, Photography, Audio, Video, Communications, Cloud, CFexpress, LCD, Science, Metadata, Architecture, Internet, DaVinci Resolve, Glass, Urinary tract infection, Skin, Blackmagic URSA, SRT, Lens, OLPF, OLED, Black Magic, Tax, RGBW, EF, Cloud storage, IDX, Blackmagic Design, Hasselblad, Multimedia, XLR, TB, RTMP, LPL, Camera

Blackmagic URSA Cine 12K is available immediately from Blackmagic Design resellers worldwide from US$14,995.

Key Points: 
  • Blackmagic URSA Cine 12K is available immediately from Blackmagic Design resellers worldwide from US$14,995.
  • (Photo: Business Wire)
    The Blackmagic URSA Cine 12K will be demonstrated on the Blackmagic Design NAB 2024 booth #SL5005.
  • Blackmagic URSA Cine 12K is available now from US$14,995, excluding local duties and taxes, from Blackmagic Design resellers worldwide.
  • Product photos of the Blackmagic URSA Cine 12K, as well as all other Blackmagic Design products, are available at www.blackmagicdesign.com/media/images .

Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsight

Retrieved on: 
Thursday, April 25, 2024
Sentinel, Conditional sentence, FDA, Kidney, Nursing care plan, Urinary tract infection, Risk, Prevalence, CDC, 3i, Diabetes, Machine learning, Artificial intelligence, Intensive care unit, Urine, Patient safety, CKD, Dehydration, Patient, Operating, LAS, Data collection, Data management, Health, System, Chronic kidney disease, Intensive care medicine, Algorithm, Overalls, CE marking, Medical device

LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.

Key Points: 
  • LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.
  • Notable urine output monitoring systems companies such as BD, Potrero Medical Inc., 3i Group plc, Serenno Medical, RenalSense Ltd., FIZE Medical, and several others, are currently operating in the urine output monitoring systems market.
  • To read more about the latest highlights related to the urine output monitoring systems market, get a snapshot of the key highlights entailed in the Global Urine Output Monitoring Systems Market Report
    Urine output monitoring systems play a crucial role in healthcare settings, offering real-time insights into a patient's renal function and overall health status.
  • To know more about why North America is leading the market growth in the urine output monitoring systems market, get a snapshot of the Urine Output Monitoring Systems Market Outlook
    The urine output monitoring systems market dynamics are witnessing significant evolution driven by several factors.

Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsight

Retrieved on: 
Thursday, April 25, 2024
Sentinel, Conditional sentence, FDA, Kidney, Nursing care plan, Urinary tract infection, Risk, Prevalence, CDC, 3i, Diabetes, Machine learning, Artificial intelligence, Intensive care unit, Urine, Patient safety, CKD, Dehydration, Patient, Operating, LAS, Data collection, Data management, Health, System, Chronic kidney disease, Intensive care medicine, Algorithm, Overalls, CE marking, Medical device

LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.

Key Points: 
  • LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.
  • Notable urine output monitoring systems companies such as BD, Potrero Medical Inc., 3i Group plc, Serenno Medical, RenalSense Ltd., FIZE Medical, and several others, are currently operating in the urine output monitoring systems market.
  • To read more about the latest highlights related to the urine output monitoring systems market, get a snapshot of the key highlights entailed in the Global Urine Output Monitoring Systems Market Report
    Urine output monitoring systems play a crucial role in healthcare settings, offering real-time insights into a patient's renal function and overall health status.
  • To know more about why North America is leading the market growth in the urine output monitoring systems market, get a snapshot of the Urine Output Monitoring Systems Market Outlook
    The urine output monitoring systems market dynamics are witnessing significant evolution driven by several factors.

Stop subsidizing Drax's forest destruction, environmental injustices, and climate damage, say Dogwood Alliance and other environmental groups

Retrieved on: 
Thursday, April 25, 2024
Carbon, Dogwood Alliance, Climate change, Burns, BBC, BECCS, Climate, Health, Electricity, Government, Growth, Plant, Environment, Tree, Urinary tract infection, Noise, Wood, Soil, CBC, Annual report, Atmosphere, Asthma, NAACP, Southern United States, Air pollution

 WASHINGTON, April 25, 2024 /PRNewswire/ -- As Drax stakeholders gather for the giant biomass company's annual general meeting on April 25 in London, community leaders, scientists, and activists on both sides of the Atlantic are calling for an end to the logging, wood-pellet making, and burning that is harming communities and forests in the U.S. and Canada, polluting the air in Europe and Asia, and contributing to climate change that affects the entire planet.

Key Points: 
  • "We want both the U.S. and the U.K. to hear our pleas to stop burning wood for energy.
  • "With its global reach and continuing drive for government support, Drax is becoming one of the world's most dangerous forest destroyers.
  • And still, the company tries to frame its efforts as climate-friendly and good for the environment," said Adam Colette of Dogwood Alliance.
  • Drax is betting big on an expensive and largely unproven technology called Bioenergy with Carbon Capture and Storage, or BECCS.

Revvity's EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

Retrieved on: 
Thursday, April 25, 2024
Partnership, PCR, European, Real-time, STI, Urinary tract infection, Patient, Immunodeficiency, IVDR

This collaboration brings together EUROIMMUN's extensive distribution network and support infrastructure with ALPCO-GeneProof's innovative molecular diagnostic technologies.

Key Points: 
  • This collaboration brings together EUROIMMUN's extensive distribution network and support infrastructure with ALPCO-GeneProof's innovative molecular diagnostic technologies.
  • "Entering into the partnership with ALPCO-GeneProof, EUROIMMUN is relying on an established and experienced provider for molecular diagnostic assays.
  • It will allow EUROIMMUN's customers to benefit from a vastly expanded high-quality assay portfolio that can be run on established real-time PCR cyclers," says Dirk Beecker, CEO of EUROIMMUN.
  • The agreement will see EUROIMMUN delivering a comprehensive portfolio of 42 molecular diagnostic assays from ALPCO-GeneProof.

FDA Approves New Treatment for Uncomplicated Urinary Tract Infections

Retrieved on: 
Wednesday, April 24, 2024
Urine, UTI, FDA, Public, Patient, Staphylococcus, Urinary tract infection, Pivmecillinam, Priority review, Safety, Woman, Cosmetics, Food, Dietary supplement, Heated tobacco product, Infection, Research, Human services, Bacteria, Nausea, Staphylococcus saprophyticus, Escherichia coli, Porphyria, Vaccine, History, Female, Therapy, System, Tablet, Diarrhea, Hypersensitivity, Multimedia, Animal, Proteus mirabilis, Clinical trial, Metabolic disorder, Division, Ibuprofen

SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

Key Points: 
  • SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
  • "The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs."
  • Uncomplicated UTIs are bacterial infections of the bladder in females with no structural abnormalities of their urinary tract.
  • Approximately one-half of all women experience at least one UTI in their lifetime.